Astellas Pharma Inc. ('Astellas') updated the information about Astellas terminated R&D programs on 'Contact for Potential Acquisition of Astellas' R&D programs' section on its corporate website.
Astellas has been working on the effective utilization of its assets from programs for which it has terminated R&D by considering the continuation of R&D that uses external resources and redevelopment for other indications. This endeavor is part of this effort, and the company is planning to post some of its terminated programs on the website successively to widely recruit potential parties. Through this, we hope to deliver new treatment options for patients suffering from diseases with high unmet medical needs.
Location: 2-5-1, Nihonbashi-Honcho
Chuo-Ku, Tokyo 103-8411
Main phone line: +81-3-3244-3000
(C) 2021 Electronic News Publishing, source ENP Newswire